Unlock stock picks and a broker-level newsfeed that powers Wall Street. Upgrade Now
XETRA - Delayed Quote EUR

Bayer Aktiengesellschaft (BAYN.DE)

Compare
22.05
+0.38
+(1.73%)
At close: February 21 at 5:39:25 PM GMT+1
Loading Chart for BAYN.DE
DELL
  • Previous Close 21.67
  • Open 21.78
  • Bid --
  • Ask --
  • Day's Range 21.74 - 22.22
  • 52 Week Range 18.41 - 31.03
  • Volume 4,048,308
  • Avg. Volume 3,453,591
  • Market Cap (intraday) 21.662B
  • Beta (5Y Monthly) 1.03
  • PE Ratio (TTM) --
  • EPS (TTM) -0.89
  • Earnings Date Mar 5, 2025
  • Forward Dividend & Yield 0.11 (0.50%)
  • Ex-Dividend Date Apr 28, 2025
  • 1y Target Est 27.50

Bayer Aktiengesellschaft operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents, as well as cell and gene therapy. The Consumer Health segment markets nonprescription over-the-counter medicines, medical products, medicated skincare products, nutritional supplements, and self-care solutions in dermatology, nutritional supplements, pain and cardiovascular risk prevention, digestive health, allergy, and cold and cough. The Crop Science segment offers chemical and biological crop protection products, improved plant traits, seeds, digital solution, and pest and weed control products, as well as customer service for agriculture. This segment provides breeding, propagation, and production/processing of seeds, including seed dressing. It has a collaboration agreement with MD Anderson Cancer Center to develop oncology drugs; research and license agreement with Dewpoint Therapeutics, Inc. for the development of new treatments for cardiovascular and gynecological diseases; collaboration agreement with Exscientia Ltd, Foundation Medicine Inc., and Evotec AG; research collaboration with Arvinas Inc.; strategic research partnership with University of Oxford to develop novel gynecological therapies; Kyoto University to identify new drugs candidates for the treatment of pulmonary diseases; and collaboration and license agreement with Cytokinetics for the development and commercialization of aficamten. It distributes its products through wholesalers, pharmacies and pharmacy chains, supermarkets, online and other retailers, and hospitals, as well as directly to farmers. The company was founded in 1863 and is headquartered in Leverkusen, Germany.

www.bayer.com

94,245

Full Time Employees

December 31

Fiscal Year Ends

Recent News: BAYN.DE

View More

Performance Overview: BAYN.DE

Trailing total returns as of 2/21/2025, which may include dividends or other distributions. Benchmark is

.

YTD Return

BAYN.DE
14.17%
DAX P
11.95%

1-Year Return

BAYN.DE
23.47%
DAX P
30.20%

3-Year Return

BAYN.DE
55.08%
DAX P
51.30%

5-Year Return

BAYN.DE
65.06%
DAX P
64.13%

Compare To: BAYN.DE

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: BAYN.DE

View More

Valuation Measures

Annual
As of 2/21/2025
  • Market Cap

    21.66B

  • Enterprise Value

    53.95B

  • Trailing P/E

    --

  • Forward P/E

    1.66

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    0.46

  • Price/Book (mrq)

    0.71

  • Enterprise Value/Revenue

    1.15

  • Enterprise Value/EBITDA

    5.76

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    -1.88%

  • Return on Assets (ttm)

    5.11%

  • Return on Equity (ttm)

    -2.73%

  • Revenue (ttm)

    46.74B

  • Net Income Avi to Common (ttm)

    -880M

  • Diluted EPS (ttm)

    -0.89

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    6.34B

  • Total Debt/Equity (mrq)

    134.10%

  • Levered Free Cash Flow (ttm)

    5.47B

Research Analysis: BAYN.DE

View More

Company Insights: BAYN.DE

Research Reports: BAYN.DE

View More

People Also Watch